|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ANKRD52-DYRK2 (FusionGDB2 ID:HG283373TG8445) |
Fusion Gene Summary for ANKRD52-DYRK2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ANKRD52-DYRK2 | Fusion gene ID: hg283373tg8445 | Hgene | Tgene | Gene symbol | ANKRD52 | DYRK2 | Gene ID | 283373 | 8445 |
| Gene name | ankyrin repeat domain 52 | dual specificity tyrosine phosphorylation regulated kinase 2 | |
| Synonyms | ANKRD33 | - | |
| Cytomap | ('ANKRD52')('DYRK2') 12q13.3 | 12q15 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit CCVWG5837PP6-ARS-Cankyrin repeat domain 33ankyrin repeat domain-containing protein 52protein phosphatase 6 ankyrin repeat subunit Cserine/threonine-protein phosphatase 6 regula | dual specificity tyrosine-phosphorylation-regulated kinase 2dual specificity tyrosine-(Y)-phosphorylation regulated kinase 2 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q8NB46 | Q92630 | |
| Ensembl transtripts involved in fusion gene | ENST00000267116, ENST00000548241, | ||
| Fusion gene scores | * DoF score | 12 X 13 X 5=780 | 8 X 5 X 7=280 |
| # samples | 11 | 8 | |
| ** MAII score | log2(11/780*10)=-2.82597060022495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(8/280*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ANKRD52 [Title/Abstract] AND DYRK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ANKRD52(56641277)-DYRK2(68050886), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | ANKRD52-DYRK2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ANKRD52-DYRK2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | DYRK2 | GO:0006468 | protein phosphorylation | 11311121 |
| Tgene | DYRK2 | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 17349958 |
| Tgene | DYRK2 | GO:0045725 | positive regulation of glycogen biosynthetic process | 11311121 |
| Fusion gene breakpoints across ANKRD52 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across DYRK2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | ACC | TCGA-OR-A5K9-01A | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + |
Top |
Fusion Gene ORF analysis for ANKRD52-DYRK2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-5UTR | ENST00000267116 | ENST00000393555 | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + |
| 5CDS-intron | ENST00000267116 | ENST00000537632 | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + |
| In-frame | ENST00000267116 | ENST00000344096 | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + |
| intron-3CDS | ENST00000548241 | ENST00000344096 | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + |
| intron-5UTR | ENST00000548241 | ENST00000393555 | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + |
| intron-intron | ENST00000548241 | ENST00000537632 | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000267116 | ANKRD52 | chr12 | 56641277 | - | ENST00000344096 | DYRK2 | chr12 | 68050886 | + | 10607 | 2306 | 44 | 3913 | 1289 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000267116 | ENST00000344096 | ANKRD52 | chr12 | 56641277 | - | DYRK2 | chr12 | 68050886 | + | 0.00015869 | 0.99984133 |
Top |
Fusion Genomic Features for ANKRD52-DYRK2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| ANKRD52 | chr12 | 56641276 | - | DYRK2 | chr12 | 68050885 | + | 6.81E-08 | 0.9999999 |
| ANKRD52 | chr12 | 56641276 | - | DYRK2 | chr12 | 68050885 | + | 6.81E-08 | 0.9999999 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for ANKRD52-DYRK2 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:56641277/chr12:68050886) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ANKRD52 | DYRK2 |
| FUNCTION: Putative regulatory subunit of protein phosphatase 6 (PP6) that may be involved in the recognition of phosphoprotein substrates. | FUNCTION: Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. Functions in part via its role in ubiquitin-dependent proteasomal protein degradation. Functions downstream of ATM and phosphorylates p53/TP53 at 'Ser-46', and thereby contributes to the induction of apoptosis in response to DNA damage. Phosphorylates NFATC1, and thereby inhibits its accumulation in the nucleus and its transcription factor activity. Phosphorylates EIF2B5 at 'Ser-544', enabling its subsequent phosphorylation and inhibition by GSK3B. Likewise, phosphorylation of NFATC1, CRMP2/DPYSL2 and CRMP4/DPYSL3 promotes their subsequent phosphorylation by GSK3B. May play a general role in the priming of GSK3 substrates. Inactivates GYS1 by phosphorylation at 'Ser-641', and potentially also a second phosphorylation site, thus regulating glycogen synthesis. Mediates EDVP E3 ligase complex formation and is required for the phosphorylation and subsequent degradation of KATNA1. Phosphorylates TERT at 'Ser-457', promoting TERT ubiquitination by the EDVP complex. Phosphorylates SIAH2, and thereby increases its ubiquitin ligase activity. Promotes the proteasomal degradation of MYC and JUN, and thereby regulates progress through the mitotic cell cycle and cell proliferation. Promotes proteasomal degradation of GLI2 and GLI3, and thereby plays a role in smoothened and sonic hedgehog signaling. Plays a role in cytoskeleton organization and neurite outgrowth via its phosphorylation of DCX and DPYSL2. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. Can phosphorylate histone H1, histone H3 and histone H2B (in vitro). Can phosphorylate CARHSP1 (in vitro). {ECO:0000269|PubMed:11311121, ECO:0000269|PubMed:12588975, ECO:0000269|PubMed:14593110, ECO:0000269|PubMed:15910284, ECO:0000269|PubMed:16511445, ECO:0000269|PubMed:16611631, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:18455992, ECO:0000269|PubMed:18599021, ECO:0000269|PubMed:19287380, ECO:0000269|PubMed:22307329, ECO:0000269|PubMed:22878263, ECO:0000269|PubMed:23362280, ECO:0000269|PubMed:9748265}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 106_135 | 728 | 1077.0 | Repeat | Note=ANK 4 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 139_168 | 728 | 1077.0 | Repeat | Note=ANK 5 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 172_201 | 728 | 1077.0 | Repeat | Note=ANK 6 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 205_234 | 728 | 1077.0 | Repeat | Note=ANK 7 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 238_267 | 728 | 1077.0 | Repeat | Note=ANK 8 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 271_301 | 728 | 1077.0 | Repeat | Note=ANK 9 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 305_334 | 728 | 1077.0 | Repeat | Note=ANK 10 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 338_367 | 728 | 1077.0 | Repeat | Note=ANK 11 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 371_400 | 728 | 1077.0 | Repeat | Note=ANK 12 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 40_69 | 728 | 1077.0 | Repeat | Note=ANK 2 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 422_451 | 728 | 1077.0 | Repeat | Note=ANK 13 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 455_484 | 728 | 1077.0 | Repeat | Note=ANK 14 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 488_545 | 728 | 1077.0 | Repeat | Note=ANK 15 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 549_579 | 728 | 1077.0 | Repeat | Note=ANK 16 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 584_613 | 728 | 1077.0 | Repeat | Note=ANK 17 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 617_646 | 728 | 1077.0 | Repeat | Note=ANK 18 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 651_680 | 728 | 1077.0 | Repeat | Note=ANK 19 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 687_716 | 728 | 1077.0 | Repeat | Note=ANK 20 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 73_102 | 728 | 1077.0 | Repeat | Note=ANK 3 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 7_36 | 728 | 1077.0 | Repeat | Note=ANK 1 |
| Tgene | DYRK2 | chr12:56641277 | chr12:68050886 | ENST00000344096 | 1 | 3 | 222_535 | 66 | 602.0 | Domain | Protein kinase | |
| Tgene | DYRK2 | chr12:56641277 | chr12:68050886 | ENST00000393555 | 0 | 2 | 222_535 | 0 | 529.0 | Domain | Protein kinase | |
| Tgene | DYRK2 | chr12:56641277 | chr12:68050886 | ENST00000344096 | 1 | 3 | 228_236 | 66 | 602.0 | Nucleotide binding | ATP | |
| Tgene | DYRK2 | chr12:56641277 | chr12:68050886 | ENST00000344096 | 1 | 3 | 301_304 | 66 | 602.0 | Nucleotide binding | ATP | |
| Tgene | DYRK2 | chr12:56641277 | chr12:68050886 | ENST00000393555 | 0 | 2 | 228_236 | 0 | 529.0 | Nucleotide binding | ATP | |
| Tgene | DYRK2 | chr12:56641277 | chr12:68050886 | ENST00000393555 | 0 | 2 | 301_304 | 0 | 529.0 | Nucleotide binding | ATP |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 720_749 | 728 | 1077.0 | Repeat | Note=ANK 21 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 753_782 | 728 | 1077.0 | Repeat | Note=ANK 22 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 790_819 | 728 | 1077.0 | Repeat | Note=ANK 23 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 822_852 | 728 | 1077.0 | Repeat | Note=ANK 24 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 857_886 | 728 | 1077.0 | Repeat | Note=ANK 25 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 890_920 | 728 | 1077.0 | Repeat | Note=ANK 26 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 924_953 | 728 | 1077.0 | Repeat | Note=ANK 27 |
| Hgene | ANKRD52 | chr12:56641277 | chr12:68050886 | ENST00000267116 | - | 20 | 28 | 960_989 | 728 | 1077.0 | Repeat | Note=ANK 28 |
Top |
Fusion Gene Sequence for ANKRD52-DYRK2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >4765_4765_1_ANKRD52-DYRK2_ANKRD52_chr12_56641277_ENST00000267116_DYRK2_chr12_68050886_ENST00000344096_length(transcript)=10607nt_BP=2306nt AGGCGGGGCCGCGCTCTCCCTGCAGCCGCCACCGCAGCCGCCGCCTGGGCCGCTCCGTGTCCCCGGTGGAGCCGCCGCCGCCGCCGCCGG GAGCTCGATGCGGACGGAGCCCGGGCCGAGCCATGGGGATCCTCAGCATCACGGACCAGCCGCCCCTGGTCCAGGCCATCTTTAGCCGAG ATGTGGAGGAAGTGCGTTCCCTACTCTCGCAGAAGGAGAACATCAATGTGCTGGACCAAGAGAGGCGAACTCCATTGCATGCTGCTGCCT ACGTAGGCGATGTCCCCATCCTCCAGTTGCTACTGATGTCAGGTGCTAATGTCAATGCTAAGGACACACTGTGGCTGACCCCTCTTCATC GTGCTGCTGCCTCCCGAAACGAGAAGGTGCTGGGGCTGCTGCTGGCACATTCAGCAGATGTGAATGCCCGGGACAAGCTGTGGCAGACAC CACTGCATGTGGCTGCTGCCAACCGGGCCACCAAGTGTGCTGAGGCTCTGGCACCCCTGTTGAGCAGCCTCAACGTGGCTGACAGGAGCG GGCGCAGTGCTCTGCACCATGCAGTGCATAGTGGGCATCTTGAGACGGTGAACCTGCTCCTCAACAAGGGAGCCAGCCTGAATGTCTGTG ACAAAAAGGAGCGGCAGCCTCTGCATTGGGCAGCTTTTCTAGGGCACTTGGAGGTCCTAAAACTGCTGGTGGCACGGGGAGCAGACCTCG GCTGCAAGGACCGCAAGGGCTATGGGCTGCTCCATACAGCTGCTGCCAGTGGCCAGATTGAAGTGGTGAAGTACCTGCTTCGGATGGGAG CGGAGATCGATGAACCCAATGCTTTTGGAAACACAGCTTTGCACATCGCCTGCTACCTGGGCCAGGATGCTGTGGCTATTGAGCTGGTGA ATGCCGGAGCCAATGTCAACCAGCCGAATGACAAGGGCTTCACGCCACTGCATGTGGCTGCAGTCTCCACCAATGGCGCTCTCTGCTTGG AGCTACTGGTTAATAATGGGGCTGACGTCAACTACCAGAGCAAAGAAGGGAAAAGTCCTCTGCACATGGCTGCAATCCATGGCCGTTTCA CACGCTCCCAGATCCTCATCCAGAATGGCAGCGAGATTGATTGTGCCGACAAATTTGGGAACACGCCACTGCATGTGGCTGCTCGATATG GACACGAGCTGCTCATCAGCACCCTCATGACCAATGGCGCAGATACCGCCCGGCGTGGCATCCATGACATGTTCCCCCTGCACTTAGCTG TTCTCTTTGGATTCTCTGACTGTTGTCGTAAGCTTCTTTCCTCAGGTCAGTTGTACAGCATTGTGTCTTCACTCAGCAATGAGCATGTGC TTTCAGCTGGGTTTGACATCAATACACCTGACAACCTTGGCCGTACCTGTCTTCATGCTGCTGCTTCCGGAGGGAATGTTGAATGTCTTA ATTTGCTGTTGAGCAGTGGAGCTGACTTGAGGAGGAGGGACAAATTTGGCAGGACCCCACTGCACTATGCAGCTGCTAACGGTAGCTACC AGTGTGCAGTAACATTGGTGACTGCTGGGGCAGGTGTCAACGAGGCCGACTGTAAAGGCTGCTCTCCCCTCCACTACGCTGCCGCTTCTG ACACTTACAGGAGAGCGGAACCCCATACACCTTCCAGCCATGATGCCGAAGAGGACGAGCCACTGAAGGAGTCCCGCAGGAAGGAGGCCT TCTTCTGTCTGGAGTTCTTACTGGATAACGGTGCAGACCCCTCCCTGCGGGACAGGCAGGGCTACACAGCTGTGCACTATGCAGCCGCCT ATGGCAACAGACAGAACCTCGAACTGCTCTTAGAAATGTCCTTTAACTGCCTGGAGGATGTGGAGAGCACCATTCCAGTCAGCCCTTTGC ACTTAGCTGCCTACAACGGTCACTGTGAAGCCTTGAAGACGCTGGCGGAGACGCTGGTGAATCTGGACGTAAGGGACCACAAGGGCCGGA CCGCACTCTTCCTGGCCACGGAGCGCGGCTCTACTGAGTGTGTGGAGGTGCTTACAGCCCACGGCGCCTCTGCCCTCATCAAGGAGCGCA AGCGCAAGTGGACACCCCTGCACGCTGCTGCTGCCTCTGGCCACACTGACTCCCTGCACTTGCTGATCGACAGTGGGGAACGAGCTGACA TCACAGATGTCATGGATGCCTATGGACAGACCCCACTGATGCTGGCCATCATGAATGGCCATGTGGACTGTGTACATCTGCTGCTAGAGA AAGGATCCACAGCTGATGCTGCTGACCTCCGGGGCCGCACTGCCCTCCACCGCGGGATTGGCGGCAGTAAGCACACAATGAATGATCACC TGCATGTCGGCAGCCACGCTCACGGACAGATCCAGGTTCAACAGTTGTTTGAGGATAACAGTAACAAGCGGACAGTGCTCACGACACAAC CAAATGGGCTTACAACAGTGGGCAAAACGGGCTTGCCAGTGGTGCCAGAGCGGCAGCTGGACAGCATTCATAGACGGCAGGGGAGCTCCA CCTCTCTAAAGTCCATGGAAGGCATGGGGAAGGTGAAAGCCACCCCCATGACACCTGAACAAGCAATGAAGCAATACATGCAAAAACTCA CAGCCTTCGAACACCATGAGATTTTCAGCTACCCTGAAATATATTTCTTGGGTCTAAATGCTAAGAAGCGCCAGGGCATGACAGGTGGGC CCAACAATGGTGGCTATGATGATGACCAGGGATCATATGTGCAGGTGCCCCACGATCACGTGGCTTACAGGTATGAGGTCCTCAAGGTCA TTGGGAAGGGGAGCTTTGGGCAGGTGGTCAAGGCCTACGATCACAAAGTCCACCAGCACGTGGCCCTAAAGATGGTGCGGAATGAGAAGC GCTTCCACCGGCAAGCAGCGGAGGAGATCCGAATCCTGGAACACCTGCGGAAGCAGGACAAGGATAACACAATGAATGTCATCCATATGC TGGAGAATTTCACCTTCCGCAACCACATCTGCATGACGTTTGAGCTGCTGAGCATGAACCTCTATGAGCTCATCAAGAAGAATAAATTCC AGGGCTTCAGTCTGCCTTTGGTTCGCAAGTTTGCCCACTCGATTCTGCAGTGCTTGGATGCTTTGCACAAAAACAGAATAATTCACTGTG ACCTTAAGCCCGAGAACATTTTGTTAAAGCAGCAGGGTAGAAGCGGTATTAAAGTAATTGATTTTGGCTCCAGTTGTTACGAGCATCAGC GTGTCTACACGTACATCCAGTCGCGTTTTTACCGGGCTCCAGAAGTGATCCTTGGGGCCAGGTATGGCATGCCCATTGATATGTGGAGCC TGGGCTGCATTTTAGCAGAGCTCCTGACGGGTTACCCCCTCTTGCCTGGGGAAGATGAAGGGGACCAGCTGGCCTGTATGATTGAACTGT TGGGCATGCCCTCACAGAAACTGCTGGATGCATCCAAACGAGCCAAAAATTTTGTGAGCTCCAAGGGTTATCCCCGTTACTGCACTGTCA CGACTCTCTCAGATGGCTCTGTGGTCCTAAACGGAGGCCGTTCCCGGAGGGGGAAACTGAGGGGCCCACCGGAGAGCAGAGAGTGGGGGA ACGCGCTGAAGGGGTGTGATGATCCCCTTTTCCTTGACTTCTTAAAACAGTGTTTAGAGTGGGATCCTGCAGTGCGCATGACCCCAGGCC AGGCTTTGCGGCACCCCTGGCTGAGGAGGCGGTTGCCAAAGCCTCCCACCGGGGAGAAAACGTCAGTGAAAAGGATAACTGAGAGCACCG GTGCTATCACATCTATATCCAAGTTACCTCCACCTTCTAGCTCAGCTTCCAAACTGAGGACTAATTTGGCGCAGATGACAGATGCCAATG GGAATATTCAGCAGAGGACAGTGTTGCCAAAACTTGTTAGCTGAGCTCACGTCCCCTGATGCTGGTAACCTGAAAGATACGACATTGCTG AGCCTTACTGGGTTGAAAAGGAGTAGCTCAGACCTGTTTTTATTTGCTCAATAACTCTACTCATTTGTATCTTTTCAGCACTTAATTTTA ATGTAAGAAAGTTGTTCATTTTGTTTTTATAAAATACATGAGGACAATGCTTTAAGTTTTTATACTTTCAGAAACTTTTTGTGTTCTAAA AGTACAATGAGCCTTACTGTATTTAGTGTGGCAGAATAATAACATCAGTGGCAGGCCACTGATTACTTCATGACTGCCACGCATTTACAG ATTGGTGTCAAAGACATTCACTATGTTTTTATGGTTCATGTTATATCCTCCCCAGGGTGACAGCCCCTTAAGGCCCTCCTTTTCCCTCCA TGCTCCAGGTCCATGCACAGGTGTAGCATGTCCTGCTTCCGTTTTTCATAAATTAATCTGGGTGTTGGGGGTAGTGGGAGGAGAACGGTC AGAATCAAAGTGACATTCTAAGAAAAACTGTACCTTAGAGATTTTCCTCTAGTGCTCAAACAAATACAAAATAAGATCCCCAAGGTTTAA ACTGCCCAGTTAGCATTCTGACATTCTAAAAGCCGGCAAAGCAGCTTTTAGTGGATAAATGGGAATGGAAACGTGTGTGTTCCTCCAAAT TTTCTAGTATGATCGGTGAGCTGTTTTGTAAAGAAGCCTCATATTACAGAGTTGCTTTTGCACCTAAATTTAGAATTGTATTCCATGAAC TGTTCCTCCCTTTTCTCTGCTTTTCTCCTCTCTGTTCCTCTTTTAATACCACACGTCTGTTGCTTGCATTTAGTTTGTCTTCTTCCTTCA GCTGTGTATCCCAGACTGTTAATACAGAAAAGAGACATTTCAGCTGTGATTATGACCATTGTTTCATATTCCAATTAAAAAAAGAACAGC AGCCTAGCTACTTAAGGTGGGGATTTCCATAGTTCCAAAGAAGATTTAGCAGATTAGAGTGAGTTCACACTTTTCAGGTGCCACTGTAAG GTTCTCTCAGCCTGGGAAACTATCAACTCTTTCTTTAAAAAGAAAGAGGGTTGAAAATCCTCTGGACGAACAGAAGTCACTTTGGCTGTT CAGTAAGGCCAATGTTAACAACACGTTTAGAGGAGGAAAAGTTCAACCTCAAGTTAAATGGTTTGACTTATTCTTCGTATCATTAGAAGA ACCCCAGAGATAGCATTCCTCTATTTTATTTTACTTTCTTTTGGATTGCACTGATTGTTTTTGTGGGAATGACACTTTATCTGGCAAAGT AACTGAGAGTTTGGTAAAAGAATATTTTCTTCTCTGAATAATAATTATTTTCACAGTGAAAATTTCAGTATTTTATCACTAATGTATGAG CAATGATCTATATCAATTTCAAGGCACGTGAAAAAAATTTTTTAGTATGTGCAATTTAATATAGAAAGATTTCTGCCTGTTTGGACAATA GGTTTTGGGTAGTACAGATTAGGATAAGTAAGCTTATATATGCACAGAGATTATTGTATTACCTGTAAATTGATTTACAAGTACTTAAAA GCGTGGTCCCCAGTGAGGCCAAGAAAGTTTCCGGTTAAGTTCTTTAATAATAATCCTACAGTTTATCTTAAGAAAAAAAAAAAGGTTTGA AAAAAACACTTTAATTTAGGCTTCGTTGGTTGATGGTGGAAAAAAATGCTCAGGAAATATTTCAGATATTTGCCAAAAAACCAGTAATAA GGTTACCTTATTAAAATAGTGATATTTGCTTTACTATTTAAGGTGTCACTGATAAATTAATTTGTACTTCTGTGTTTAGAAATTATAGCT TCTTTTCCCTTAGTCAAATTTTTTAGCATATTATACACATTTCTGTGTAATCTGTGGAAGTGCAATAATATGTTAGTAAGTTACATTTTA AATAATGCTCATGTGACAATACTCCCAATCAATGGCTTATAGAATTTAAAGATCTGTATATTAGATTTTGGCTTAAAGGCATGAGAAGTA TAAGACTTGGTTTGGTGGCTTTGTAAGACCACCAGCCTCTTAATGATGGTTAGCTTCTTTAGGTCATTAAATCAATAAAAACATATAATG CTGTTTTGCTCTTCTAATGCTCCTCTTCCATTTCCAGTTATCTTCACATTTACATTTAAATATACAAACCTGAGCCTGCCATTATTAATT TCCCTATAAAATGACGATACATGTGAACATTTATAAATGGACTAATACTGCTTGTCTTTCCCCCACCGCACAAAACTGGTTCTTAAGATG CCAGCAATGAATTTGAGACTATCTTTATTTATAAATGGAAACCGGAAACTTTTATACCAAACTATAATAATGTGCAGCACTGTAGGGCTT TTTTTTTTTTCCCTCCAAATACAGTGAAATTTTTTTATTCACAAGAGCTGCCACATCTCAGCATTTAGTAATAGAGCTGCTTTAATAAAA TTCTAGTTTGATTGTCATGTCAAAAAAAGAAAAATGTTGCATCTTTGTGATTTTAAAACATAAATTAATGAAGGCTCTGATAGGCTATTA GGAGTTGGCTTGGAAACAGTTTTTGGTCTCACAGGTTACCATTGTTTGGGGATGTCTGAGCTGTTTTCAGATCTAGGAATAGCACAGTGT TGTCTTGTCTTTGGCAGTCTCATTTGGCTCTGTTTCTTGCACCACCAGCGTGTTCATTACCACTTAAATATATTGCTACAGCAGTGGAAC AACAGAGTGGTGCAAGACACTGTAGATTAACGGTAGAGGAGAAATTGTGCCCTTAGTGTTAACAATGTGCCTTTTGTTCTGAATGCCATG TTGTAGGGCATGCATTTTTTGGCCTCTTTAACTCTTCGAATTCTAGTCAGTAAGAATGGAACCCATCTCTGCAAAGATACATCTGTCTTA AATATCTAGTTACAGGCCTTAATAGAAACCATAAGGCATGACTCATCTTCAGGCACTGAAAAAAGATAACCATCAGGTAGTGTTACACAA GGACTTCCTATATTTAAGGGGTTAAAGATGGTCTTTGTTGTATCTTAACATCAGACTGATTTTTACATTTTTTTTTTGTTATGCTAACAC TAGACAAAAATCAACTGTATTTGTAAAAATTTACCTCAAACCATTTAATTTTATAGTGTGATTAATCCCAGGGCATTTGGTATGAACCAA AGTGCATTCCTTTTATATGTGCCTGGCTCTAGTAAGGATGGCCAGGGATTTTTACAATTTGGGTGCAAGGCACTTAAGCCACTTTTAAAC TTAATGGGTGGTTTGGGGTCGTGTTAAATGACTCCATCAGAATGTTAGAAAACACTTTAGGCATCAGTAGCATTGGGCCATATTGGAATC CTAAAGTGTGAATTATTTTAAGGAGAGCATTCATTTTTGTAATTTTTTTCATCAAAAATATTTCTGGTAAGCAGAAGACTTTTTAAAAAA ACTGATCTGGTCTCGGTAAAGGTTTTAATATTGCCCAACATAATGCTGTAATAGCATTAAAAAAAGTATTTGTGAACTCTGTTTCTTAGG GGCTTGTACATCTCTCTGCTATGGACATACATAAAATTAATTGTAATTATACTCAGCTCAACTGCTACAGTTCTGTCTAGGCAGTGGCTT GGGTTTTTATCGAGCAACAACTTAGACACGTGACTGTAATATGCTGCAACTGTGTGTACTGAAAATATGTGAAAATGGTTGAATGTGGAC TGTGTATATATGTATGTAAAAATTTCTGTGAGATGCTGCTGTCGCCACTTAACATTAAATATGTTCTAGTGGATTTTAATCCTAGTGGCC AGTTCTATGATACTGTATGTATTATACAGCTGATGACAGGAGTAAGACTGTTTAGTGAATATCTGTTAAATTTTATTGTTGTGGCCAGAG ATAATTTCAGAATAAAATTTTAATGTCCTACCTTACTTCTCTCCCCTTTCTAACTATAATTTAACTCCTGATCTATTTCTGGTATTATCC TTTGTCAATTAGCCTGGAGAGGGTTTAGAATGCAAAATGGATAGCTCTATATCAGGGTCTTGAGAAGTTAAAATAATTCATTCTACTAGT TTGTTCATAGCAATACTTTATTAGTTCAATATAAGTATGCAGATTCCAAGTGGAAAAACAAAGGTTTTAGTAAGTAGTTCTTGCTTTTCC CAGGATATTCTATTCCTTCACCTGTCAGATTTTTATGTTAACTTTTTTATATATAGCCTCTGCTGTGTTCTTTATTATGCTAGAGCTTCA TATCTTCTTTTATTTTAACCTTCACAATGATAGTTAAGCTGGGGGAGCAGAACCTGTCAATTATTCCCCACCAGTCTTCATTCTTTTCTC TGCACAAGTTCTGGTAAATTATTCTAATGTGCTCTAACCAGTTCCACCCAATGTTTTTTAATGCTTATGAGTTTGCAGTTTTTGTACTTG GTGGTCTCTGTGGTTCACATTTTTTTGTGTTGTAGTGTCTCCTGCCTCGGTTGGCTCAGAAAATAAGGCCTAGGAACTGCAATTAGCTCA TGATTTGTCAAGTTCAGTTAGTACCAAGCTAAGAGTTTACTTACAGATGACAGCAAGCAGATGCTCTAGTAATTCGTCAGACATTGCAGG GATATTGTGTAGTCAGATATTACCCTCTTGTGGAAAGAACTACCTCACATCATTATTTATTTCCCTTCTGTTACCAACAGCCAAGGAATT ACTTAGTGTGGCTCCCTGCATCAATACTGGGATATGCTTAAACAAGGGAATGCCATAAGAGTTCCCAATTGCCTCGTCATAGCCTGGGCC ATAGATTTTTGTTACTGCTAATCTTGCTTCTTAAAGTTCACACCCAGTGCAAAAAACCCAATCAGCAAACTAACCCCAAAATCCAATATA TTTAGAAATGTAAGTGTTAAGAGATGTGCATTATGTACAAAATTGAAAATTGGTGCTAAAGTGGCAATGTCAATTTAAAATTTCTTGTCC AGATCTGACTGACTGACTCAGGAGATTATAGTTCCTACTCATTCTCTTTCCTTTTATCAGATCTTTCAAAAGCGCTTTTTAAAATTGATC AATGTGCAATTCTGTTTGAGTCTCTACAGTCCTATCCCTTTTGGAATGAACAGCTACACAAATAAATATTCTTGGAACTTCGAAGTTGTC TTCAAACTAGCTCTAGAAAATGTCCCTAGTTGACATTAGTGTTGGTCTGTTAGAAGGGGAAATTGATTTGACTGCTTCATGTTTTGAAAA GAGCATTAAGAGGGATTTGAGGAAGGTATATGTGGCTTTCTTTTTTTTTCTTAAGTTTGAATTACACTTGATTTCCTTTGGGTTATTAGG CAGATAAACCCTTGTCATTAGTAATACTTAGCACTGTCCAAAATGAAAAATGACTGCCAGTGTGTTGCACATACATAAGAAAATTACATC TTACTGCGAAGTCTTTGGTTTGTTTCCTTATTTGGTTTGACTTTGACTTACTATTTTGCTATGGTCATATCCTTAATATCTGCGGTACAT TTCATATATATATATGGGGTGGGAGCATAATTGCCATTCCCATGTGTCTCAAGGAAGCTTAATGAGGAAACTAATGAGTTAATATTAACT CTTCTGAAGAAAGCTGACATTTTAGGAGTATTAAGTCATCTGTCGTTAAGGAGCAGCAAGAATATATTATGATTGTATCACATGTTCCAG AAGAGCATTACCCCTTACATAGAAAGCTCCTTGGAGATTTCATGATGTTGGATGAACATCAGTTTATCCTTATACATCCCTATGAGCTAT AATTATCCTCATTTGATACTTGAGGAAACTGAAGTGACTTGCTCCAAAGTTGACTACAAAAACATTGCAGTTTGAGGCTTAGGTTGTAAT CAGGTAATTTTGGTCTTGGACAGTAAGGGAAAATCCATAATACATAAAACACAAAAGTTTAGAAAGGGGGGGAAGTTGAGCTAGCAATGG GCATTTCTATTATTTAAGTTACATATCAGTTTCCAGGAATATTTTTCAAATGGGACAAACTAAAAAGTTGAGGACTAGAGCATCGTAGTG TCTAAGTGCACCTAATAACTTAATGCATGTGCACACACCCTCAGTTAATTTGTAAGAGAGTGACTTCTCATTGTTATTTGTGGAGAGGCT AATTATAGTAGCTTCATTCTTTATTTTCTGTGTTCTTAAATTTTTTTTTACATTTGAAAGTATGAAAATACTATTTTTGACACTTTACTG ATACTCAGGGATTAAAAGTTAAATTTTACTGACTGTAGCAGCAGGTAAATCTCTTAAATTTACTCAGGTTTCCTATCCTTTGCCTCCATA TTTAAGAAAATATAGAATGCCTGCCAGGGAAATATATAAAAATAAAAATTTCAAATACAATTTTAAAATACCAATTTGTAAATAAACCAA TTTTACAAACTAAAATATTGTGTCTTTCCTTGCTTTTTATCCCAATTTATCTCCCCTCCTAAGTTTGAGGAGTTTTATATATTAAGGCTA TTTCTTCATTTGTAAAAATGAAGTATGCTATTTGCAAAGCAAAAGCCCATGAAAAGCCCCAAATCATTTAAGTAAAGCTTACTGAATTGT >4765_4765_1_ANKRD52-DYRK2_ANKRD52_chr12_56641277_ENST00000267116_DYRK2_chr12_68050886_ENST00000344096_length(amino acids)=1289AA_BP=754 MGRSVSPVEPPPPPPGARCGRSPGRAMGILSITDQPPLVQAIFSRDVEEVRSLLSQKENINVLDQERRTPLHAAAYVGDVPILQLLLMSG ANVNAKDTLWLTPLHRAAASRNEKVLGLLLAHSADVNARDKLWQTPLHVAAANRATKCAEALAPLLSSLNVADRSGRSALHHAVHSGHLE TVNLLLNKGASLNVCDKKERQPLHWAAFLGHLEVLKLLVARGADLGCKDRKGYGLLHTAAASGQIEVVKYLLRMGAEIDEPNAFGNTALH IACYLGQDAVAIELVNAGANVNQPNDKGFTPLHVAAVSTNGALCLELLVNNGADVNYQSKEGKSPLHMAAIHGRFTRSQILIQNGSEIDC ADKFGNTPLHVAARYGHELLISTLMTNGADTARRGIHDMFPLHLAVLFGFSDCCRKLLSSGQLYSIVSSLSNEHVLSAGFDINTPDNLGR TCLHAAASGGNVECLNLLLSSGADLRRRDKFGRTPLHYAAANGSYQCAVTLVTAGAGVNEADCKGCSPLHYAAASDTYRRAEPHTPSSHD AEEDEPLKESRRKEAFFCLEFLLDNGADPSLRDRQGYTAVHYAAAYGNRQNLELLLEMSFNCLEDVESTIPVSPLHLAAYNGHCEALKTL AETLVNLDVRDHKGRTALFLATERGSTECVEVLTAHGASALIKERKRKWTPLHAAAASGHTDSLHLLIDSGERADITDVMDAYGQTPLML AIMNGHVDCVHLLLEKGSTADAADLRGRTALHRGIGGSKHTMNDHLHVGSHAHGQIQVQQLFEDNSNKRTVLTTQPNGLTTVGKTGLPVV PERQLDSIHRRQGSSTSLKSMEGMGKVKATPMTPEQAMKQYMQKLTAFEHHEIFSYPEIYFLGLNAKKRQGMTGGPNNGGYDDDQGSYVQ VPHDHVAYRYEVLKVIGKGSFGQVVKAYDHKVHQHVALKMVRNEKRFHRQAAEEIRILEHLRKQDKDNTMNVIHMLENFTFRNHICMTFE LLSMNLYELIKKNKFQGFSLPLVRKFAHSILQCLDALHKNRIIHCDLKPENILLKQQGRSGIKVIDFGSSCYEHQRVYTYIQSRFYRAPE VILGARYGMPIDMWSLGCILAELLTGYPLLPGEDEGDQLACMIELLGMPSQKLLDASKRAKNFVSSKGYPRYCTVTTLSDGSVVLNGGRS RRGKLRGPPESREWGNALKGCDDPLFLDFLKQCLEWDPAVRMTPGQALRHPWLRRRLPKPPTGEKTSVKRITESTGAITSISKLPPPSSS -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ANKRD52-DYRK2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ANKRD52-DYRK2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ANKRD52-DYRK2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | C0238198 | Gastrointestinal Stromal Tumors | 1 | CTD_human | |
| Tgene | C3179349 | Gastrointestinal Stromal Sarcoma | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies